New induction and postinduction strategies in acute myeloid leukemia

Current Opinion in Hematology

Volumn 19, Issue 2, 2012, Pages 76-81

  Burnett, Alan K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

acute myeloid leukemia; chemotherapy; induction; postinduction

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CLADRIBINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; NUCLEOSIDE ANALOG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADD ON THERAPY; ANTIBODY DIRECTED CHEMOTHERAPY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; FOLLOW UP; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; DAUNORUBICIN; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MITOXANTRONE; PROGNOSIS;

EID: 84857038101     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283500a92     Document Type: Review

References (24)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341:1051-1062. (Pubitemid 29451802)
2. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453-474.
3. Burnett AK, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29:487-497.
4. Wheatley K. A systemic collaborative overview of randomised trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998; 103:100-109. (Pubitemid 28470806)
5. Todeschini G. High-dose anthracycline induction in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15:9-20. (Pubitemid 32201865)
6. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361:1249-1259. This trial demonstrates a benefit for dose escalation of daunorubicin to 90 mg/m2.
7. Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011; 118:3832-3841. This more recent trial confirms the observation seen in the ECOG trial [6& ] with longer follow-up.
8. Lowenberg B, Ossenkoppele GJ, van Putten W, et al High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009 361 1235-1248. A confirmation that daunorubicin dose escalation is also feasible in older patients.
9. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. J Clin Oncol 2010; 28:808-814.
10. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSG AML201 Study. Blood 2011; 117:2358-2365. This study illustrates the effect of dose density for daunorubicin
11. This study illustrates the effect of dose density for daunorubicin. 11. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244-3254. (Pubitemid 32591442)
12. Larson RA, Boogaerts MA, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16:1627-1636.
13. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003; 102:4277-4283. (Pubitemid 37494084)
14. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 Trial. J Clin Oncol 2011; 29:369-377.
15. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus postconsolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. ASH Annual Meeting Abstracts. Blood 2009; 114:abstr. 790.
16. Castaigne S, Pautas C, Terre C, et al. Fractionated doses of Gemtuzumab Ozogamicin (GO) combined to standard chemotherapy (CT) improve eventfree and overall survival in newly diagnosed de novo AML patients aged 50-70 years old: A prospective randomized phase 3 trial from the Acute Leukemia French Association.ASHAnnual Meeting Abstracts. Blood 2011; 118:abstr. 6.
17. Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UKNCRI AML16 randomized trial. ASH Annual Meeting Abstracts. Blood 2011; 118:abstr. 582.
18. Holowiecki J, Grosicki S, Kyrcz-Krzemien S, et al. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome -Polish Adult Leukemia Group (PALG) pilot study. Ann Hematol 2008; 87:361-367.
19. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia. Multicenter, randomized phase III study. J Clin Oncol (in press). A demonstration that cladrabine in combination with conventional daunorubicin doses is superior to Ara-C and fludarabine, except in high-risk patients where fludarabine is also beneficial.
20. Burnett AK, Hills RK, Milligan D, et al. Attempts to optimise induction and consolidation chemotherapy in patients with acute myeloid leukaemia: Results of the MRC AML15 Trial. ASH Annual Meeting Abstracts. Blood 2009; 114:abstr. 484.
21. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid-leukemia. N Engl J Med 1994; 331:896-903. (Pubitemid 24299870)
22. Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: The results of the LRF AML14 trial. Br J Haematol 2009; 145:318-332.
23. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28:549-555.
24. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28:2389-2395.